Although no highly selective BCL2A1 inhibitor has yet been identified (Li et al, 2021), a few inhibitors have shown promising results in experimental cancer studies (D de Araujo et al, 2018; Haq et al, 2013b), including the BET inhibitor CPI-0610, which indirectly targets the transcription of BCL2A1 (Yamatani et al, 2022). The gene discussed is DNER; the disease is cancer.